This study is testing a new medicine, NMRA-335140, for people with Major Depressive Disorder (MDD), which is a type of depression. It's an important study because it aims to find out if this medicine helps with depression symptoms. The study includes two parts: a Screening Period that lasts up to 35 days and a 6-week Treatment Period. During the treatment, participants will either get the new medicine or a pill with no medicine called a placebo. A placebo is used to compare results to see if the new medicine really works.
Key Points:
- The study lasts about 6 weeks and requires a screening period before starting.
- Participants need to have a diagnosis of MDD confirmed by doctors and meet specific health criteria.
- Those who complete the study may join a follow-up study where they know they are getting the medicine.
Participants with severe depression, other specific mental health conditions, or serious suicidal risks are not eligible. The study is double-blind, meaning neither the participants nor the researchers know who is getting the actual medicine or placebo, to ensure fairness in results.